Plain-English translation of NCT06503237 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is a small trial testing SWK002, a new type of treatment that uses immune cells called CAR-T cells to help control rheumatoid arthritis in patients whose disease has not improved with other medications. The study will watch closely to see if the medication is safe and whether it works to reduce joint pain and swelling. About 18 people will participate at one hospital in China.
Some people with rheumatoid arthritis do not get better even after trying multiple standard treatments, and their joints continue to be painful and swollen. This trial is exploring whether this new immune therapy approach might help patients who have already tried and failed other options.
You likely qualify if…
You likely don't qualify if…
You would receive two doses of preparatory chemotherapy drugs (cyclophosphamide and fludarabine) to prepare your body, then receive an infusion of the new immune cells on day 0. After that, you would be monitored closely by the hospital team to watch for safety concerns and to see how well the treatment works. The study team will check your blood and joints regularly and follow you to make sure the CAR-T cells are working safely in your body.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Sponsor
The First Affiliated Hospital of University of Science and Technology of China
Enrollment target
~18 participants
Started
November 2023
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhu Chen Professor of medicine, M.D.
The First Affiliated Hospital of University of Science and Technology of China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.